688098.SH
申联生物
SSE · Healthcare · Biotechnology · CN
CNY 8.00
−3.03%Year over year
Reported trailing growth
- Revenue
- -7.5%
- EBITDA
- —
- EBIT
- +53.5%
- EPS
- +57.2%
- Free cash flow
- —
- Operating cash flow
- -74.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.3%
- EBITDA
- -29.1%
- EBIT
- +50.7%
- Net income
- +54.2%
- EPS
- +54.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026